Business
Acrivon is a clinical-stage biotechnology company developing precision oncology medicines using its AP3 proteomics platform.
Acrivon trimmed burn and drew insider buying, but it remained pre-revenue with equity down 36%.
The read at a glance✓ Audited against SEC data
- Business mix — AP3 precision oncology platformNote
- Revenue — No revenue in local bundleNote
- Profitability — Net loss improved to $77.9MOK
- Cash burn — Free cash flow improved to -$65.3MOK
- Balance sheet — Equity -36.4% to $112.5MWatch
- Insiders — 3 buys / 0 sells; $114K boughtOK
- Accounting — No forensic screen in bundleNote
Leadership changes
From Acrivon Therapeutics, Inc.'s own filings, the day they're filed.
- Adam Levy · Chief Financial Officer · appointmenteff. 2025-04-01
- Rasmus Holm-Jorgensen · Chief Financial Officer · departureeff. 2025-04-01
- Santhosh Palani · director · appointmenteff. 2024-03-04
Latest filings
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-12
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Acrivon Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.